BWX Technologies, Inc. Q4 2025 Earnings Call Summary

Performance in 2025 was driven by the ability to scale operations amid robust demand across all nuclear end markets, resulting in 18% revenue growth and a 50% increase in total backlog to $7.3 billion.

The Government Operations segment secured critical new pricing agreements for naval propulsion and initiated major defense uranium enrichment and high-purity depleted uranium (HPDU) programs.

Commercial growth was accelerated by the strategic acquisitions of AOT and Kinectrics, which enabled the company to secure its first meaningful AP1000 engineering contract and expand its role in CANDU life extensions.

Management attributes the 95% revenue surge in Commercial Operations to a combination of 31% organic growth in power and medical sectors alongside the integration of Kinectrics.

Operational success in the medical portfolio reached a $100 million annual revenue milestone, supported by double-digit growth in diagnostic isotopes and actinium sales.

Strategic positioning as a ‘super merchant supplier’ allows the company to remain technology-agnostic, providing critical components and engineering to various SMR and large-scale reactor OEMs.

The company is actively evaluating a physical expansion of its Mount Vernon facility to specifically serve the U.S. commercial nuclear market, leveraging existing heavy-lift infrastructure.

2026 guidance anticipates high-teens revenue growth, with over half of the Government Operations growth expected from the ramp-up of defense fuels and HPDU contracts.

Commercial Operations are projected to achieve 25% growth in 2026, driven by low double-digit gains in nuclear power and high-teens growth in the medical isotopes business.

Management expects a 100 basis point margin expansion in Commercial Operations for 2026 as revenue scales and the business mix normalizes following recent acquisitions.

The 2026 financial framework assumes a slightly higher tax rate of approximately 22% due to a greater proportion of international earnings from the expanding Kinectrics and commercial power businesses.

Capital expenditures are planned at approximately 6% of sales to build out capacity for anticipated long-term demand in both the defense and commercial nuclear sectors.

Government Operations margins are expected to be slightly lower in 2026 due to the ‘initial profit recognition’ phase of new large-scale programs which carry higher initial execution risks.

The company successfully executed a $1.25 billion convertible debt offering with a 0% coupon to optimize its balance sheet and enhance liquidity for future M&A and organic investments.

Management noted that 2026 earnings will be more back-half weighted than usual, with approximately 55% of full-year EBITDA expected in the second half due to program timing and mix.

The Tech-99 medical product remains in a ‘grilling last mile’ of development due to product quality and filtration issues, with no revenue from this product included in the 2026 guidance.